Deals relating to regenerative medicine decreased significantly in the pharmaceutical industry in H1 2022

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

Deals relating to regenerative medicine in the pharma sector have decreased by 40% from H1 2021 to H1 2022, an analysis of GlobalData's deals database reveals.

Powered by 

In the first half of 2022 the number of deals relating to regenerative medicine decreased significantly by 40% from the same period in 2021. 

This marks a deceleration in growth from the 27.6% decrease in deals that occurred in H2 2021 relative to the same period a year earlier. 

GlobalData's deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During first half of 2022, deals relating to regenerative medicine accounted for 4.9% of all deals taking place in the sector. This represents a decrease from the figure of 6.7% in the first half of 2021.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter. 

These themes, of which regenerative medicine is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.